NASDAQ:IMNM Immunome Q3 2026 Earnings Results & Report $19.36 +0.65 (+3.47%) Closing price 04:00 PM EasternExtended Trading$18.65 -0.71 (-3.67%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Immunome missed analyst earnings expectations in its Q3 2026 results, released November 9, 2026. The company reported EPS of -$0.76 versus the -$0.6085 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 9, 2026TimeAfter Market ClosesConference Call4:00 PM ET Immunome EPS ResultsActual EPS-$0.76Consensus EPS -$0.6085Beat/MissMissed by -$0.1515One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersImmunome Revenue ResultsActual RevenueN/AExpected Revenue$154 thousandBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Immunome Q3 2026 Earnings FAQ Did Immunome beat earnings estimates for Q3 2026? Immunome (NASDAQ:IMNM) reported earnings of -$0.76 per share for Q3 2026, missing the consensus estimate of -$0.6085. The report was announced on Monday, November 9, 2026. Immunome Earnings HeadlinesImmunome to Present at Guggenheim 3rd Annual Healthcare Innovation ConferenceNovember 2, 2026 | businesswire.comImmunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid TumorsOctober 30, 2026 | businesswire.comTesla pays zero dividends but this new fund pays monthlyTesla has never paid shareholders a dividend, not one cent. A new fund built on Tesla's stock takes a different approach, paying $452 in monthly cash on a $5,000 stake. Elon Musk recently floated a Tesla-SpaceX merger, but the dividend gap remains unchanged. Similar funds now exist for Apple, Amazon, Microsoft and Nvidia, each designed to turn big tech exposure into monthly income.November 9 at 1:00 AM | Investors Alley (Ad)Immunome Advances Varegacestat Capsule Study, Signaling Steady R&D ProgressOctober 29, 2026 | tipranks.comImmunome (NASDAQ:IMNM) Earns "Outperform" Rating from WedbushOctober 29, 2026 | americanbankingnews.comWilliam Blair initiates coverage of Immunome at outperformOctober 17, 2026 | msn.comSee More Immunome Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immunome? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunome and other key companies, straight to your email. Email Address About ImmunomeImmunome (NASDAQ:IMNM) is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use. Immunome became a publicly traded company in 2023 following a merger with Morphimmune and a combination with Ayala Pharmaceuticals. The company is based in the United States and conducts research and clinical development, with trials that may involve sites in multiple countries.View Immunome ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6IonQ's Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength RemainsThe Ugly Truth Behind SoundHound’s Q3 Results Upcoming Earnings Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026)Honda Motor (11/11/2026)Franco-Nevada (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
